Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset

July 9, 2026 02:17 PM EDT R&D Roche ends work on tomin­ersen af­ter decade of tri­als, as well as ear­ly-stage Hunt­ing­ton’s as­set Lei Lei Wu News Reporter Af­ter more than a decade of work and plen­ty of ups and downs, Roche has dropped its Hunt­ing­ton’s dis­ease drug tomin­ersen. The de­ci­sion comes af­ter … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER